Navigation Links
AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
Date:6/29/2009

    GAI-122, an investigational injectable nanoemulsion formulated with
    AlphaRx's proprietary drug delivery technology, providing significant
    neuro-protection in multiple in vitro and in vivo studies which suggest
    that this injectable nanoemulsion formulation has the potential to
    prevent postoperative delirium

MARKHAM, ON, June 29 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited today reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia.

Delirium is a common mental disorder with serious adverse outcomes in post-operative hospitalized patients. It is associated with an increase in mortality, physical morbidity, length of hospital stay, institutionalization of patients and increased cost to healthcare providers. Ten to thirty percent of admissions of patients over 65 years of age to a general hospitals develop delirium after surgery and the incidence rate can be as high as 50% in patients who undergone high risk and lengthy procedures such as hip replacement and cardiac surgeries. There is no preventive therapy currently available for post-operative delirium.

"There are over 10,000,000 inpatient surgeries performed annually in the U.S. on patients over the age of 65, and up to 40% of these seniors will develop post-operative delirium. There is an urgent need to develop a medicine, such as GAI-122 injectable nanoemulsion, for the preventive of this debilitating post-operative condition," said Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx.

In rat model studies, injected GAI-122 ameliorates learning and memory disturbances produced by cerebral embolization, cerebral ischemia or lesions in the basal forebrain, the area of origin of the acetylcholine neuron system projecting into the cerebral cortex, hippocampus and amygdala. In clinical t
'/>"/>

SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. AlphaRx Shareholder Update
2. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
3. AlphaRx Signs Cooperative Research and Development Agreement with US Army
4. AlphaRx Provides Corporate and Development Update
5. AlphaRxs Indaflex(TM) Continues its Clinical Development
6. AlphaRx CEO Accumulates More Company Shares
7. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
8. AlphaRx Announces Debt Conversion
9. AlphaRx To Present at 47th Annual ICAAC
10. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
11. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... the very healthy. Astronauts are selected for their ... standards to prepare them for any unknown challenges. ... people can now fly for enjoyment. The aerospace ... what medical conditions or diseases should be considered ... medical conditions have never been studied for risk ...
(Date:9/17/2014)... who struggle to distinguish between a business strategy and business ... the answer by reading Per Wickstrom’s latest blog post. , ... plan and a business strategy are both strategic – and ... I view it is that a business plan is part ... , According to the blog post, a business plan ...
(Date:9/17/2014)... nanoparticles, gene manipulation these sound like the ... fact, they are components of an exciting new ... preclinical animal models of metastatic prostate cancer, scientists ... Institute of Molecular Medicine and Johns Hopkins Medical ... imaging approach that could revolutionize doctors, ability to ...
(Date:9/17/2014)... Somerset, N.J. (PRWEB) September 17, 2014 ... of advanced delivery technologies and development solutions for ... the launch of OptiPact™, an integrated service and ... roller compaction, and provided from the company’s 450,000 ... technology describes Catalent’s ability to integrate optimal formulation, ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Positive messages ... some people kick the habit, a new study suggests. ... responded better to "loss-framed" messages about the harmful effects ... quit whenever they want benefit more from "gain-framed," or ... The researchers concluded that using a mix of ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... promise for human protection in future , , MONDAY, Jan. 28 (HealthDay ... one day ward off the flu. , Not only would the ... it also appears to be more effective than the flu shot ... the potential to be widely accepted by people who are afraid ...
... University researchers is the first to conduct a genome-wide ... contribute to DNA mutations, which are implicated in cancer ... professor of biology Kateryna Makova, the group investigated the ... increase the susceptibility to mutations of microsatellites -- variable-length ...
... ARLINGTON, Va., Jan. 28 Noting recent crises,involving the ... of a governmental blue ribbon panel, Jim Martin, president ... Drug Administration "itself a,threat to the health and safety ... holding hearings on the state of the,FDA on January ...
... Jan. 28 The American Academy of,Pediatrics (AAP) is ... for Thursday, January 31. As reported in The New ... court that a vaccine caused a,child,s autism. While the ... autism and vaccines, the episode,s conclusion delivers a,contrary impression; ...
... of the National Institute of Child Health and Human ... for Reproduction and Infertility Research at the University of ... at expanding the science underlying the success or failure ... reproductive health. , The NICHD supports a national ...
... cancer of the pancreas increase dramatically for patients whose tumors ... Saint Louis University and the M.D. Anderson Cancer Center in ... between tumor size and survival rates for one of the ... the current edition of Pancreas ( www.pancreasjournal.com ) vividly ...
Cached Medicine News:Health News:Drop of Flu Vaccine Under Tongue Bars Infection 2Health News:Scientists explore factors contributing to DNA mutations 2Health News:Scientists explore factors contributing to DNA mutations 3Health News:Scientists explore factors contributing to DNA mutations 4Health News:Don't Overburden FDA 2Health News:American Academy of Pediatrics Calls for Cancellation of ABC's 'Eli Stone' Premiere 2Health News:National Institutes of Health funds new center for reproduction and infertility research at Illinois 2Health News:Pancreatic cancer: The smaller the tumor, the better your chances, study shows 2Health News:Pancreatic cancer: The smaller the tumor, the better your chances, study shows 3
(Date:9/17/2014)...  Lightbeam Health Solutions announced today an agreement ... ACO) to deploy the Lightbeam population health platform ... while reducing costs. Photo - ... Care Organization is the ACO operating entity of ... is to be the premier integrated health care ...
(Date:9/17/2014)... 2014 According to a new ... Battery, Memory Device, Display, & Microprocessor/MCU), by Application (Imaging, ... by Geography - Global Forecast to 2020", published by ... expected to reach $56.50 Billion by 2020, growing at ... Browse 235 market data Tables and 71 Figures ...
(Date:9/17/2014)... , Sept. 17, 2014 Women everywhere ... infections are not only uncomfortable, they,re often also embarrassing ... plans. pH-D Feminine Health Support ( http://ph-defense.com ) is ... It is an all-natural, homeopathic product. ... common symptoms of vaginal infection. In many cases, the ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4New Product from Vireo Systems: pH-D Feminine Health Support 2
... MELBOURNE, Australia, September 12, 2011   ... Spinifex Pharmaceuticals, an Australian pain drug development company, today ... EMA401 in a model of diabetic neuropathy. EMA401 is an ... development for a number of neuropathic pain indications. ...
... WASHINGTON, Pa., Sept. 10, 2011 Core Essence Orthopaedics, ... tissue and skeletal repair of the extremities, has introduced ... the 66th Annual Meeting of the American Society for ... a pioneer of surgical innovation to the upper and ...
Cached Medicine Technology:New Data on EMA401 in Model of Diabetic Neuropathy Presented at 21st Annual NEURODIAB Meeting 2New Data on EMA401 in Model of Diabetic Neuropathy Presented at 21st Annual NEURODIAB Meeting 3Core Essence Orthopaedics Unveiled New Flexor Tendon Repair System at ASSH 2011 2
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Medicine Products: